UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): ~~May~~September 62, 2010

HUIFENG BIO-PHARMACEUTICAL TECHNOLOGY, INC.

(Exact name of Registrant as specified in its charter)

Nevada	000-32253	87-0650264
(State or other jurisdiction	(Commission File Number)	(IRS Employer Identification Number)
of incorporation)

16B/F Ruixin Bldg., No. 25 Gaoxin Road

Xi’an, Shaanxi Province, China 710075

(Address of principal executive offices)

86-29-8822 4682

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o	Written communications pursuant to Rule 425 under the Securities Act

o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act

o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

ITEM 51.~~02 DEPARTURE~~01—ENTRY OFINTO ~~DIRECTORS~~A ORMATERIAL ~~CERTAIN~~DEFINITIVE ~~OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS~~AGREEMENT.

On September ~~May 6~~2, 2010, ~~Ms.~~Huifeng ~~Angela~~Bio-Pharmaceutical ~~Aichun~~Technology, LiInc., ~~resigned as~~ a ~~member~~Nevada corporation ~~of the Board of Directors~~ (the “~~Board~~Company”), ofthrough ~~Huifeng~~its ~~Bio~~wholly-~~Pharmaceutical~~owned ~~Technology~~subsidiary, Xi’an Huifeng Bio-Technic Inc. (~~the~~ “~~Company~~Xi’an Huifeng”)., ~~Ms. Li’s~~a ~~resignation~~company ~~was~~organized ~~due~~and tooperating ~~personal~~under ~~reasons~~the laws ~~and~~of ~~not~~ the ~~result~~Peoples' Republic of ~~any~~China ("PRC"), entered into an Acquisition ~~disagreement~~Agreement with ~~the~~Shangqiu ~~Company~~Kexin onRutin ~~any~~Processing ~~matter~~Ltd. ~~relating~~(“Kexin”), toa company organized and operating under the ~~Company’s operations,~~laws ~~policies~~of orthe ~~practices~~PRC (the “Acquisition Agreement”).

OnPursuant to ~~May~~the 8Acquisition Agreement, ~~2010,~~ the ~~Board~~Company ~~appointed~~agreed ~~Mr.~~to ~~Chi~~purchase ~~Keung~~90% ~~Lui~~of asthe aequity of ~~director~~Kexin for $140,000 in cash and 2,300,000 restricted shares of the Company,'s ~~effective~~common ~~immediately. The~~stock ~~Board~~at ~~has~~a ~~determined~~per share ~~that~~price Mrof $0.7. In ~~Lui~~addition, isthe anCompany, through ~~independent~~its ~~director~~subsidiary ~~within~~Xi’an ~~the~~Huifeng, ~~meaning~~has ~~set~~agreed ~~forth~~to inloan ~~the~~Kexin ~~applicable rules~~$1,000,000, asat a 10% ~~currently~~annual ininterest ~~effect. In~~rate, ~~connection~~to ~~with~~help ~~the~~Kexin ~~appointment~~reach ofits ~~the~~projected ~~new~~annual net income of ~~director~~$650,000 tofor the ~~Board~~next three years; provided, ~~the~~however, ~~Company~~that ~~has~~should ~~agreed~~Kexin fail to achieve ~~pay~~average ~~Mr.~~projected ~~Lui~~annual annet ~~annual compensation~~income of 30$650,000 ~~shares~~in of the ~~Company’s~~next ~~restricted~~two ~~common stock. The~~years, ~~biographical~~the ~~information~~annual ~~regarding~~interest ~~the~~rate ~~new~~shall ~~director~~be isadjusted ~~listed below:~~to 20%.

~~Mr. Lui~~The ~~has~~foregoing ~~more~~description ~~than thirty year’s experience in banking, accounting and finance, information technology, and investment and business consultant. Mr. Lui is currently the CEO~~ of Porcheers Consultants Limited, a consulting company to provide professional services to corporations in internal control, public listing, acquisition and merger and corporate planning and investment. From 2004 to 2006, Mr. Lui was the ~~Director~~Acquisition ~~and~~Agreement ~~CFO~~does ofnot ~~China~~purport ~~Digital Media Corporation, a company listed on OTCBB. As the CFO of the China Digital Media Corporation, Mr. Lui assisted the company~~ to be ~~listed on OTCBB and to establish the accounting~~ ~~and~~complete ~~financial system~~ and ~~implement~~is ~~the~~qualified ~~internal~~in ~~control~~its ~~system~~entirety toby ~~comply~~an ~~with the~~English ~~U.S.~~translation ~~listing requirements. Mr. Lui was also the founder and Managing Director~~ of ~~Beth Group for building ERP system from 1995 to 2001. Prior to Beth Group, Mr. Lui was~~ the ~~Director and General Manager of Tomson Pacific, a Hong~~ ~~Kong~~Acquisition ~~listed~~Agreement ~~company~~attached ~~with~~hereto ~~total assets of more than HK$3 billion. Prior to Tomson Pacific, Mr. Lui was in the merchant banking field from 1989 to 1992 to advise companies for listing in Hong Kong and act~~ as ~~consultant~~Exhibit ~~for merger and acquisition~~10.1 ~~Mr. Lui graduated from Baptist University, majoring in Business Management,~~ and ~~minoring~~incorporated inherein ~~Accounting. Mr. Lui obtained his MBA degree~~by ~~from the University of East Asia in Macau~~reference.

The Company does not anticipate that Xi’an Huifeng’s acquisition of Kexin will trigger any reporting requirements under Item 2.01 of this Form 8-K.

ITEM 3.02— UNREGISTERED SALES OF EQUITY SECURITIES.

As described in Item 1.01 of this Report on Form 8-K, pursuant to the Acquisition Agreement the Company has agreed to issue 2,300,000 restricted shares of the Company's common stock to the former shareholders of Kexin within one month of the date of the Acquisition Agreement. These shares will not be registered under the Securities Act of 1933, as amended (the “1933 Act”) pursuant to an exemption from registration provided by Section 4 (2) of the 1933 Act.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.		Description
10.1		English translation of Acquisition Agreement by and between Xi’an Huifeng Biochemistry Ltd. and Shangqiu Kexin Rutin Processing Ltd. effective as of September 2, 2010.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Huifeng Bio-Pharmaceutical Technology, Inc.
	By:	/s/ Jing’an Wang
		Jing’an Wang
Date: May 11, 2010		Chief Executive Officer
Date: September 8, 2010		Chief Executive Officer

Filing Compare · Huifeng Bio-Pharmaceutical Technology, Inc.